Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma

[1]  T. Hsiau,et al.  Inference of CRISPR Edits from Sanger Trace Data. , 2022, The CRISPR journal.

[2]  L. Bullinger,et al.  Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9 , 2021, Leukemia.

[3]  D. Vignali,et al.  Interferon-γ: teammate or opponent in the tumour microenvironment? , 2021, Nature Reviews Immunology.

[4]  F. Klauschen,et al.  Comprehensive micro-scaled proteome and phosphoproteome characterization of archived retrospective cancer repositories , 2021, Nature Communications.

[5]  Weili Zhao,et al.  CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis , 2021, Signal Transduction and Targeted Therapy.

[6]  W. Brenner,et al.  Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? – A preclinical assessment in vitro and in vivo , 2020, Neoplasia.

[7]  Bryan J. Venters,et al.  Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture , 2020, Nature.

[8]  Andrew J. Dunford,et al.  Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. , 2019, Blood advances.

[9]  Lauren C. Chong,et al.  Mutational Landscape of Grey Zone Lymphoma. , 2019, Blood.

[10]  Andrew J. Dunford,et al.  Genomic Analyses of PMBL Reveal New Drivers and Mechanisms of Sensitivity to PD-1 Blockade. , 2019, Blood.

[11]  S. Sleijfer,et al.  Pan-cancer whole-genome analyses of metastatic solid tumours , 2019, Nature.

[12]  K. Basso,et al.  Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma. , 2019, Immunity.

[13]  Lauren C. Chong,et al.  Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. , 2019, Blood.

[14]  Catherine L. Worth,et al.  The Translational Landscape of the Human Heart , 2019, Cell.

[15]  Shridar Ganesan,et al.  All-FIT: Allele-Frequency-based Imputation of Tumor Purity from High-Depth Sequencing Data , 2019, bioRxiv.

[16]  D. Klatzmann,et al.  Interleukin-1 in the Response of Follicular Helper and Follicular Regulatory T Cells , 2019, Front. Immunol..

[17]  S. Tsunoda,et al.  Age-related remodelling of oesophageal epithelia by mutated cancer drivers , 2019, Nature.

[18]  S. Lowe,et al.  Histone Demethylase LSD1 is required for Germinal Center formation and BCL6-driven lymphomagenesis , 2018, Nature Immunology.

[19]  Alexander V Penson,et al.  Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. , 2018, Blood.

[20]  Stefano Monti,et al.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.

[21]  W. Kim.  Faculty of 1000 evaluation for The 2016 revision of the World Health Organization classification of lymphoid neoplasms. , 2017 .

[22]  Nicholas A. Sinnott-Armstrong,et al.  An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues , 2017, Nature Methods.

[23]  K. Hogquist,et al.  Directing T cell fate: How thymic antigen presenting cells coordinate thymocyte selection. , 2017, Seminars in cell & developmental biology.

[24]  Qi Liu,et al.  Deacetylase activity of histone deacetylase 3 is required for productive VDJ recombination and B-cell development , 2017, Proceedings of the National Academy of Sciences.

[25]  A. Rosenwald,et al.  Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. , 2016, Blood.

[26]  K. Basso,et al.  Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis , 2015, Nature Medicine.

[27]  Charles E. Vejnar,et al.  CRISPRscan: designing highly efficient sgRNAs for CRISPR/Cas9 targeting in vivo , 2015, Nature Methods.

[28]  B. Brors,et al.  Thymic B Cells Are Licensed to Present Self Antigens for Central T Cell Tolerance Induction. , 2015, Immunity.

[29]  N. Matsumura,et al.  IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer , 2015, British Journal of Cancer.

[30]  O. Elemento,et al.  Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. , 2015, Blood.

[31]  P. Farnham,et al.  Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha , 2014, BMC Genomics.

[32]  I. Lossos,et al.  Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas , 2014, Nature Genetics.

[33]  M. Calaminici,et al.  Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma , 2013, Nature Genetics.

[34]  O. Elemento,et al.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. , 2013, Cancer cell.

[35]  C. Riccardi,et al.  Murine B Cell Development and Antibody Responses to Model Antigens Are Not Impaired in the Absence of the TNF Receptor GITR , 2012, PloS one.

[36]  Mariano J. Alvarez,et al.  Quantitative modeling of the terminal differentiation of B cells and mechanisms of lymphomagenesis , 2012, Proceedings of the National Academy of Sciences.

[37]  Raul Rabadan,et al.  Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.

[38]  P. Opolon,et al.  TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. , 2011, Cancer cell.

[39]  Peggy J. Farnham,et al.  ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells , 2010, Oncogene.

[40]  Kearney T. W. Gunsalus,et al.  The Transcription Factor REST Is Lost in Aggressive Breast Cancer , 2010, PLoS genetics.

[41]  M. Walsh,et al.  The ZNF217 oncogene is a candidate organizer of repressive histone modifiers , 2009, Epigenetics.

[42]  K. Rajewsky,et al.  Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-κB pathway and promotes lymphomagenesis , 2008, The Journal of experimental medicine.

[43]  S. Ziegler,et al.  Local increase in thymic stromal lymphopoietin induces systemic alterations in B cell development , 2007, Nature Immunology.

[44]  K. Lindblad-Toh,et al.  Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals , 2005, Nature.

[45]  Y. Tu,et al.  Cattoretti and Riccardo Dalla-favera Tracking Cd40 Signaling during Germinal Center Development , 2022 .

[46]  L. Staudt,et al.  The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-κB signal transduction pathway , 2002, Oncogene.

[47]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[48]  I. Caramalho,et al.  IFN‐α/β enhances BCR‐dependent B cell responses , 2002 .

[49]  P. Hodgkin,et al.  Integrating signals from IFN-gamma and IL-4 by B cells: positive and negative effects on CD40 ligand-induced proliferation, survival, and division-linked isotype switching to IgG1, IgE, and IgG2a. , 1999, Journal of immunology.

[50]  C. Fonatsch,et al.  Two neoplastic cell lines with unique features derived from Hodgkin's disease , 1980, International journal of cancer.

[51]  Riccardo Dalla-Favera,et al.  Germinal centres: role in B-cell physiology and malignancy , 2008, Nature Reviews Immunology.